SCHEMBL4462490

SCHEMBL4462490

Cc1ccc(S(=O)(=O)NCCCN2CC3(CCC3)Cc3cc(O)c(C)c(C)c32)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
MBTD1 Q05BQ5 1/20 0.47
CCR1 P32246 1/20 0.42
ALDH1A1 P00352 4/20 0.39
PTGES O14684 1/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
HTR1A P08908 1/20 0.37
ALOX15 P16050 1/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462547 0.94 L3MBTL1 (0.41) L3MBTL1MBTD1CCR1ALDH1A1PTGES
SCHEMBL4462823 0.86 CNR2 (0.31)
SCHEMBL4471159 0.85 ALDH1A1 (0.39) L3MBTL1ALDH1A1KMT2ATSHRSMN1; SMN2
SCHEMBL4464001 0.73 ALDH1A1 (0.39) L3MBTL1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL4467896 0.69 KCNJ1 (0.39)
SCHEMBL4463140 0.66 HSD17B10 (0.31) HSD17B10
SCHEMBL4478726 0.66 DRD2 (0.42) L3MBTL1KMT2AMEN1
SCHEMBL23682795 0.65 L3MBTL1 (1.00) L3MBTL1MBTD1CCR1ALDH1A1KMT2A
SCHEMBL4464667 0.65
SCHEMBL14039394 0.64 L3MBTL1 (0.97) L3MBTL1MBTD1CCR1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 L3MBTL1 2776/4885MBTD1 2608/4885CCR1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.